Coverage
-
April 20, 2021
Illumina's fight with the Federal Trade Commission over its $8 billion plan to buy cancer testing company Grail will take place in California federal court after a D.C. judge decided that a Golden State venue would be more convenient for witnesses.
4 other articles on this case.
View all »